SciSparc 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Oz Adler

최고 경영자

US$379.0k

총 보상

CEO 급여 비율	83.1%
CEO 임기	6.6yrs
CEO 소유권	n/a
경영진 평균 재임 기간	6.6yrs
이사회 평균 재임 기간	8.4yrs

최근 관리 업데이트

Recent updates

SciSparc to acquire an American food supplements and cosmetics brand in ~$20M deal

Aug 15

SciSparc board of directors to promote buyback program of up to $1M

Jul 06

SciSparc completes development of SCI-110 to treat tourette syndrome

Jun 29

CEO 보상 분석

Oz Adler 의 보수는 SciSparc 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$6m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$379k	US$315k	-US$5m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	US$287k
Mar 31 2023	n/a	n/a	-US$1m
Dec 31 2022	US$549k	US$358k	-US$3m
Sep 30 2022	n/a	n/a	-US$6m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$7m
Dec 31 2021	US$297k	US$223k	-US$6m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$3m
Dec 31 2020	US$301k	US$188k	-US$3m
Sep 30 2020	n/a	n/a	-US$4m
Jun 30 2020	n/a	n/a	-US$5m
Mar 31 2020	n/a	n/a	-US$4m
Dec 31 2019	US$258k	US$189k	-US$5m
Sep 30 2019	n/a	n/a	-US$5m
Jun 30 2019	n/a	n/a	-US$5m
Mar 31 2019	n/a	n/a	-US$9m
Dec 31 2018	US$230k	US$184k	-US$6m

보상 대 시장: Oz 의 총 보상 ($USD 379.00K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 652.28K ).

보상과 수익: Oz 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Oz Adler (37 yo)

6.6yrs

테뉴어

US$379,000

보상

Mr. Oz Adler, CPA, is Independent External Director of Rail Vision Ltd since June 2022. He is Independent Director of Polyrizon Ltd. from September 2021.He has been Independent Director at Clearmind Medic...

리더십 팀

이름	위치	테뉴어	보상	소유권
Oz Adler	CEO & CFO	6.6yrs	US$379.00k	데이터 없음
Itschak Shrem	President & Director	2.8yrs	US$235.00k	0.0095% $ 80.9
Adi Zuloff-Shani	Chief Technologies Officer	8.8yrs	US$296.00k	데이터 없음

6.6yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: SPRC 의 관리팀은 노련하고 경험 (평균 재직 기간 6.6 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Itschak Shrem	President & Director	4.3yrs	US$235.00k	0.0095% $ 80.9
Daniele Piomelli	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Elon Eisenberg	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
James Leckman	Member of Scientific Advisory Board	8.4yrs	데이터 없음	데이터 없음
Joseph Tam	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kirsten Müller-Vahl	Member of Scientific Advisory Board	8.4yrs	데이터 없음	데이터 없음
Michael Davidson	Member of Scientific Advisory Board	8.4yrs	데이터 없음	데이터 없음
Avi Weizman	Member of Scientific Advisory Board	8.4yrs	데이터 없음	데이터 없음
Michael Bloch	Member of Scientific Advisory Board	8.4yrs	데이터 없음	데이터 없음
Amitai Weiss	Chairman of the Board	4.3yrs	US$235.00k	0.00070% $ 6.0
Mellar Davis	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Amnon Shay	Independent Director	3.8yrs	데이터 없음	데이터 없음

8.4yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: SPRC 의 이사회는 경험(평균 재직 기간 8.4 년)으로 간주됩니다.

SciSparc 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

SciSparc Ltd., Annual General Meeting, Oct 01, 2024

Insufficient new directors

SciSparc Ltd., Annual General Meeting, Aug 15, 2023

SciSparc Ltd., Annual General Meeting, Aug 11, 2022

Recent updates

New minor risk - Financial data availability

An undisclosed buyer signed a letter of intent to acquire 52.73% stake in MitoCareX Bio Ltd from SciSparc Ltd. (NasdaqCM:SPRC).

An undisclosed buyer signed a letter of intent to acquire 52.73% stake in MitoCareX Bio Ltd from SciSparc Ltd. (NasdaqCM:SPRC).

SciSparc Takes Major Step Forward with IND Application Submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc -Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

SciSparc Ltd. Submits IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

SciSparc Ltd., Annual General Meeting, Oct 01, 2024

SciSparc Ltd Announces Enrollment of the First Five Patients in the Clinical Trial of Its Innovative Sci-210 Treatment

New minor risk - Share price stability

SciSparc Ltd. (NasdaqCM:SPRC) signed a merger agreement to acquire remaining stake in Automax Motors Ltd (TASE:AMX).

SciSparc Ltd. Announces Successfully Dosed the First Patient in Its SCI-210 Clinical Trial At the Soroka Medical Center for Pediatric Patients

Investor sentiment deteriorates as stock falls 16%

SciSparc Ltd. Announces Enrollment of First Patient for Its Clinical Trial for Children with Autism Spectrum Disorder

Scisparc Ltd. Granted Patent for Core Technology in Multiple Jurisdictions in Europe

Investor sentiment improves as stock rises 17%

Insufficient new directors

Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder

Investor sentiment improves as stock rises 68%

SciSparc Ltd. announced that it expects to receive $20 million in funding from Yorkville Advisors Global LP

Investor sentiment deteriorates as stock falls 18%

Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Scisparc Ltd. Obesity Drug Showed Positive Results in A Pre-Clinical Trial

SciSparc Ltd. Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment

SciSparc Ltd. Announces Initiation of its Phase IIb Clinical Trial Treatments with its SCI-110, Proprietary Drug Candidate

SciSparc Ltd. Receives Patent from the Australian Patent Office for Its Reduction of Opioids Use in Pain Management Technology

SciSparc Ltd. Receives Notice of Acceptance for Its Core Technology Application for the Combinations of Cannabinoids and N-Acylethanolamines

Investor sentiment improves as stock rises 85%

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Ltd. announced that it expects to receive $5.018281 million in funding

SciSparc Ltd. announced that it expects to receive $5.018281 million in funding

SciSparc Ltd. Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S

SciSparc Ltd., Annual General Meeting, Aug 15, 2023

SciSparc Ltd. Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

Scisparc Ltd. Announces Irb Approval to Conduct Its Phase Iib Trial in Tourette Syndrome

New major risk - Share price stability

Capital Point Ltd. Files Suit Against SciSparc Ltd

SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center

SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial

Scisparc Announces Positive Study Results with Sci-210, A Cannabidiol-Based Treatment for Epilepsy

SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

SciSparc Ltd. Announces Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation

Scisparc Ltd. Announces its Scisparc Nutraceuticals Inc. Successfully Launches New Keto Gummies Apple Cider Vinegar Product

SciSparc Announces Receipt of Nasdaq Minimum Bid Price Notification

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of Its Psychedelic-Based Pharma Collaboration with Clearmind Medicine Inc

SciSparc to acquire an American food supplements and cosmetics brand in ~$20M deal

SciSparc Ltd. Receives Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders

SciSparc Ltd. Announces Israeli Ministry of Health Approval to Conduct Its Clinical Trial in Autism Spectrum Disorder

SciSparc Ltd., Annual General Meeting, Aug 11, 2022

SciSparc Ltd. (NasdaqCM:SPRC) announces an Equity Buyback for $1 million worth of its shares.

SciSparc board of directors to promote buyback program of up to $1M

SciSparc Ltd. Completes Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study in Tourette Syndrome

SciSparc completes development of SCI-110 to treat tourette syndrome

SciSparc Ltd. Announces Ethics Committee Approval to Conduct Clinical Trial in Autism Spectrum Disorder

Clearmind Medicine Inc. and SciSparc Ltd Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors

SciSparc Ltd. announced that it expects to receive $10 million in funding

SciSparc Ltd. Announces Ethics Committee Approval to Conduct A Phase IIb Trial in Tourette Syndrome

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

SciSparc Ltd. and Clearmind Medicine Inc. Collaborations Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors

SciSparc Ltd. Announces Recruitment of First Patient for Its Phase IIa Clinical Trial in Alzheimer's Disease

SciSparc Ltd. Ordinary Shares Deleted from Other OTC

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령